According to Makary and Prasad, the US’s adoption of a “one-size-fits-all” guidance for COVID-19 vaccination departs from ...

Nucleoside reverse transcriptase inhibitors appear to be neuroprotective, thus lowering the incidence of Alzheimer dementia.

The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was ...

The approval in previously treated pediatric patients was based on data from the Alfa-PROTECT and PROTECT Kids studies.

AD109 is a once daily pill that consists of aroxybutynin, an antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor.

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

No gynecological malignancies were seen, while expected incidence was 0.26 or greater for all cancer types. HealthDay News — Short-term testosterone use among transmasculine and gender diverse ...

"As policymakers debate whether to enact drastic cuts to Medicaid funding, they should consider the possibility that doing so could similarly disrupt chronic disease therapy for children.